Display options
Cite
Saffra NA, Seidman CJ, Weiss LM. Ocular Toxoplasmosis: Controversies in Primary and Secondary Prevention. J Neuroinfect Dis. 2013;4
Saffra, N. A., Seidman, C. J., & Weiss, L. M. (2013). Ocular Toxoplasmosis: Controversies in Primary and Secondary Prevention. Journal of neuroinfectious diseases, 4.
Saffra, Norman A, et al. "Ocular Toxoplasmosis: Controversies in Primary and Secondary Prevention." Journal of neuroinfectious diseases vol. 4 (2013).
Saffra NA, Seidman CJ, Weiss LM. Ocular Toxoplasmosis: Controversies in Primary and Secondary Prevention. J Neuroinfect Dis. 2013;4. PMID: 24380083; PMCID: PMC3874278.
Copy Download .nbib Format: NLM
Share it on

J Neuroinfect Dis. 2013;4.

Ocular Toxoplasmosis: Controversies in Primary and Secondary Prevention.

Journal of neuroinfectious diseases

Norman A Saffra, Carly J Seidman, Louis M Weiss

Affiliations

  1. Division of Ophthalmology, Maimonides Medical Center, Brooklyn, NY 11219, USA ; Department of Ophthalmology, New York University, New York, NY 10016, USA.
  2. Departments of Medicine and Pathology, Albert Einstein College of Medicine, Yeshiva University, Bronx, NY 10461, USA.

PMID: 24380083 PMCID: PMC3874278

Abstract

Ocular toxoplasmosis is the most common cause of posterior uveitis in the United States and worldwide. It commonly follows a relapsing course with the potential for multiple adverse visual sequelae and, rarely, blindness. Both immune-competent and immune-suppressed populations can develop severe relapsing disease. There is considerable debate regarding the initial treatment of ocular toxoplasmosis in both groups, with multiple antiparasitic agents commonly used with little evidence to support any particular regimen. The precise role of corticosteroids in treatment also has yet to be rigorously defined. Secondary prevention is commonly implemented in the immune suppressed population, but there is a lack of level one evidence to support its role in immune-competent patients, though it warrants future investigation.

Keywords: antiparasitic therapy; chemoprophylaxis; infectious retinal disease; ocular toxoplasmosis; retinochoroiditis; secondary prevention

References

  1. Ophthalmology. 2002 May;109(5):869-78 - PubMed
  2. Br J Ophthalmol. 1998 Nov;82(11):1306-8 - PubMed
  3. Cochrane Database Syst Rev. 2002;(1):CD002218 - PubMed
  4. Med Sci Monit. 2012 May;18(5):CR296-302 - PubMed
  5. Lancet. 2004 Jun 12;363(9425):1965-76 - PubMed
  6. Ocul Immunol Inflamm. 2011 Feb;19(1):2-9 - PubMed
  7. Am J Ophthalmol. 2004 Jan;137(1):1-17 - PubMed
  8. Ophthalmology. 2011 Jan;118(1):134-41 - PubMed
  9. Clin Infect Dis. 2003 Nov 15;37(10):e147-8 - PubMed
  10. J Clin Microbiol. 1999 Nov;37(11):3465-8 - PubMed
  11. Am J Ophthalmol. 2002 Jul;134(1):41-6 - PubMed
  12. Int Ophthalmol. 1998-1999;22(2):85-8 - PubMed
  13. Ophthalmic Surg Lasers. 2001 May-Jun;32(3):183-92 - PubMed
  14. Ophthalmology. 2013 Feb;120(2):371-8 - PubMed
  15. Am J Trop Med Hyg. 2010 Mar;82(3):464-5 - PubMed
  16. J Fr Ophtalmol. 1987;10(1):15-23 - PubMed
  17. Am J Ophthalmol. 2002 Jul;134(1):102-14 - PubMed
  18. Semin Ophthalmol. 2005 Jul-Sep;20(3):129-41 - PubMed
  19. Mem Inst Oswaldo Cruz. 2009 Mar;104(2):345-50 - PubMed
  20. Ophthalmology. 2005 Nov;112(11):1876-82 - PubMed

Publication Types

Grant support